Comparative Biochemistry and Physiology D-Genomics & Proteomics, published by Elsevier Science Inc, is a premier journal in the realm of molecular biology and comparative physiology, with a focus on genomic and proteomic sciences. Recognized for its high-impact contributions, it holds a Q1 ranking in Animal Science and Zoology and was established with the vision of bridging gaps in our understanding of biological systems through experimental and comparative approaches. With an impressive Scopus ranking, this journal not only ranks among the top 12% in Animal Science and Zoology but also demonstrates commendable standings across various categories including Aquatic Science and Molecular Biology. The journal’s commitment to disseminating high-quality research makes it an essential resource for researchers, professionals, and students alike, allowing them to access critical studies that influence advancements in genomics and proteomics. While it operates under a traditional subscription model, its impactful findings are crucial for those aiming to enrich their knowledge and research capabilities in these pivotal scientific fields. Join us in exploring the transformative insights and developments that this esteemed journal has to offer for the study of genomics and proteomics.

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

BIOINFORMATICS, published by Oxford University Press, is a leading journal in the realms of biochemistry, computational mathematics, and computer science, with a notable impact factor that underscores its significance in the field. Since its inception in 1985 and continuing through its expected convergence in 2024, the journal has maintained a prestigious reputation, proudly residing in the Q1 category across multiple disciplines, including molecular biology and statistics. With a Scopus ranking placing it within the top percentiles of its categories, BIOINFORMATICS serves as an essential platform for disseminating high-quality research that advances knowledge and innovation at the intersection of biology and computational sciences. This journal not only offers both subscription and open access options, ensuring wider availability of its cutting-edge research, but it has also become a crucial resource for researchers, professionals, and students aiming to stay at the forefront of bioinformatics and related fields. Explore the latest findings and trends that define the future of biological research through this esteemed publication, any inquiries regarding the journal can be directed to its offices located at Great Clarendon St, Oxford OX2 6DP, England.

PROTEIN AND PEPTIDE LETTERS is a prominent peer-reviewed journal published by Bentham Science Publishers Ltd, specializing in the dynamic fields of biochemistry and structural biology. With an ISSN of 0929-8665 and a corresponding E-ISSN of 1875-5305, the journal has been a pivotal platform for researchers since its inception in 1994. Spanning various aspects of protein and peptide research, it aims to disseminate groundbreaking findings that enhance our understanding of molecular mechanisms and therapeutic applications. Although categorized in the Q3 quartile for biochemistry and medicine, and Q4 in structural biology within the 2023 metrics, it remains a valuable resource in the academic arena, offering insight into the latest research and advancements. As the journal converges towards its 2024 milestone, it continues to reflect the evolving landscape of molecular research. While it currently does not offer open access, the accessibility to its impactful content is essential for students, professionals, and researchers invested in these critical scientific disciplines.

Protein Journal, published by Springer, stands as a significant academic resource in the fields of Analytical Chemistry, Biochemistry, Bioengineering, and Organic Chemistry. Since its inception in 1996, the journal has dedicated itself to the dissemination of high-quality research focused on protein chemistry and its biomedical applications. With an impressive impact reflected in its classification as a Q2 journal in Analytical Chemistry and Q3 in both Biochemistry and Bioengineering as of 2023, it provides an essential platform for researchers and practitioners to share their findings. The journal embraces the open-access model, enhancing accessibility to cutting-edge research. The Protein Journal is crucial for academicians, industry professionals, and students, catering to their need for rigorous scientific discourse and innovative discoveries in protein studies. With an established track record of converging over two decades of knowledge and research, it continues to influence and shape the advancements in this vital area of science.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, published by Elsevier, is a prestigious academic journal that serves as a vital resource for researchers, professionals, and students in the fields of biochemistry, biophysics, and proteomics. With an ISSN of 1570-9639 and an E-ISSN of 1878-1454, this journal features high-impact research articles aimed at advancing our understanding of protein structure, function, and interactions, contributing significantly to both theoretical and applied sciences. Recognized for its quality, it proudly holds a Q1 ranking in Analytical Chemistry and Biophysics, and Q2 in Biochemistry for 2023, alongside notable Scopus rankings that reflect its influence in the realm of molecular biology. The journal's commitment to disseminating essential findings supports the ongoing evolution of proteomic sciences and encourages collaborative discourse among the global scientific community. For aspiring authors, the journal offers open access options, enabling broad visibility of their work. Join the conversation in this dynamic field and contribute to shaping the future of protein research!

PROTEOMICS is a leading journal focused on the rapidly evolving field of proteomics, published by WILEY in Germany. With a solid reputation established since its inception in 2001, it has continually contributed to the understanding of protein functions and interactions within biological systems. As part of its commitment to academic excellence, PROTEOMICS is ranked in the second quartile for both Biochemistry and Molecular Biology categories (2023), reflecting its significant influence in advancing research in these areas. Although it does not currently provide open access options, it remains a vital resource for researchers, professionals, and students keen to explore innovative methodologies and findings in proteomic research. By publishing groundbreaking studies that bridge theoretical knowledge with practical applications, PROTEOMICS plays a crucial role in enhancing our understanding of molecular processes and driving forward advancements in the life sciences.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.

Expert Review of Proteomics, published by TAYLOR & FRANCIS LTD, is a distinguished journal that focuses on the latest advancements in the field of proteomics, a critical area within biochemistry and molecular biology. With an ISSN of 1478-9450 and E-ISSN 1744-8387, this journal has been pivotal in disseminating high-quality research from its inception in 2004 to its planned convergence in 2024. Its influential position is reflected in its 2023 rankings, placing it in the Q2 category for both Biochemistry and Molecular Biology, alongside respectable Scopus rankings that rank it 118th and 141st in its respective categories. Despite its non-open access structure, Expert Review of Proteomics provides researchers and professionals with a vital platform for critical reviews and insights into proteomic methodologies, thus contributing significantly to the global scientific community. By bridging theoretical research with practical applications, it serves as an essential resource for those dedicated to advancing their knowledge and expertise in this dynamic field.

Journal of Proteomics, published by Elsevier, is an esteemed peer-reviewed journal dedicated to advancing research in the field of proteomics, with broad implications for biochemistry and biophysics. Established in 2008, the journal has continuously evolved, embracing innovative methodologies and technologies that facilitate protein analysis from a variety of biological systems. With its current standing in the Q2 category for both biochemistry and biophysics as of 2023, it is recognized as a significant contributor to scientific literature. The journal publishes original research articles, reviews, and methodological advancements, providing invaluable insights for researchers, professionals, and students alike. Although it does not offer open access, the journal remains a crucial platform for disseminating knowledge that informs various applications, ranging from drug development to disease understanding. As it converges towards 2024, the Journal of Proteomics continues to solidify its role in shaping the future of proteomic research through rigorous scientific inquiry and innovation.